Vaccine strategies to trigger HIV antibodies against the virus' high-mannose sugar patch

Adjuvant, mimicry and booster requirements for shepherding the development of neutralizing antibodies to the high-mannose patch on HIV-1

NIH-funded research Simon Fraser University · NIH-11160591

This project tries vaccine ingredients and schedules to help people at risk of HIV make broad antibodies that target a sugar-rich patch on the virus.

Quick facts

Grant typeR01 grant
Study typeNIH-funded research
Funding institutionSimon Fraser University NIH-funded
Lab location1 site (Burnaby, Canada)
Project IDNIH-11160591 on NIH RePORTER

What this research studies

Researchers are designing a vaccine component that mimics a specific sugar cluster (the high-mannose patch) on the HIV envelope and linking it to carrier proteins. They will test different adjuvants and booster schedules to guide B cells toward making broadly neutralizing antibodies against that sugar patch. The team measures antibody binding, affinity, and neutralization in laboratory and preclinical models to compare designs. Successful combinations would be candidates for future human vaccine testing.

Who could benefit from this research

Good fit: Ideal candidates for future trials would be adults at increased risk of HIV exposure who are willing to receive experimental vaccine doses and attend follow-up visits.

Not a fit: People with active HIV infection or with certain immunosuppressive conditions may not benefit from this preventive vaccine approach.

Why it matters

Potential benefit: If successful, this work could lead to a vaccine that helps the immune system produce broadly neutralizing antibodies that prevent HIV infection.

How similar studies have performed: Most past vaccine attempts to induce antibodies against the high-mannose patch have largely failed, so this antigen-mimic plus adjuvant strategy is relatively novel.

Where this research is happening

Burnaby, Canada

Researchers

About this research

  1. This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
  2. Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
  3. For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions Acquired Immune Deficiency Syndrome VirusAcquired Immunodeficiency Syndrome Virus
Last reviewed 2026-06-10 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.